Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27979621 | 0.91 | — | — | |
| SCHEMBL26317513 | 0.91 | TSHR (0.43) | CYP1A2HRH2HRH1ALDH1A1TSHR | |
| SCHEMBL10621821 | 0.85 | CYP1A2 (0.46) | CYP1A2TDP1HTR1ATP53CYP2C19 | |
| SCHEMBL21428422 | 0.83 | CYP1A2 (0.45) | CYP1A2TDP1HTR1ATP53CYP2C19 | |
| Hydrochloric Acid SCHEMBL15254285 | 0.83 | CYP1A2 (0.45) | CYP1A2TDP1HTR1ACYP2C19HSD17B10 | |
| SCHEMBL12184259 | 0.83 | PIK3CD (0.48) | CYP1A2TDP1HRH2HRH1KDM4E | |
| SCHEMBL5412873 | 0.82 | ALDH1A1 (0.42) | CYP1A2ALDH1A1TSHRGPR119NPC1 | |
| SCHEMBL2654623 | 0.82 | TSHR (0.40) | CYP1A2HRH2HRH1ALDH1A1TSHR | |
| SCHEMBL24715746 | 0.81 | GPR119 (0.36) | CYP1A2HRH2HRH1ALDH1A1TSHR | |
| SCHEMBL17244903 | 0.81 | HRH3 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389223-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | Universität Regensburg (DE) | 2024-06-26 | — | — | EP | disclosed |
| US-20230382913-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230302142-A1 | Cytotoxic Agents | Pheon Therapeutics Ltd. (GB) | 2023-09-28 | — | — | US | disclosed |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2023001905-A1 | NOVEL ANTIFUNGAL COMPOUNDS | SELMOD GMBH (CH) | 2023-01-26 | — | — | WO | disclosed |
| CN-114763342-A | Synthesis method of high-purity 4-methylpiperazine-1-formic ether | 江苏天士力帝益药业有限公司 | 2022-07-19 | — | — | CN | disclosed |
| WO-2022023735-A1 | CYTOTOXIC AGENTS | FEMTOGENIX LIMITED (GB) | 2022-02-03 | — | — | WO | disclosed |
| US-20210380605-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| CN-113552241-A | Method for determining residual content of 4-methylpiperazine-1-formate genotoxic impurities in zopiclone | 江苏天士力帝益药业有限公司 | 2021-10-26 | — | — | CN | disclosed |
| US-20210316006-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2021-10-14 | — | — | US | disclosed |
| US-20100009954-A1 | BETA-LACTAMASE INHIBITORY COMPOUNDS | SOUTHERN METHODIST UNIVERSITY | 2010-01-14 | — | — | US | disclosed |
| US-7491724-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20080214572-A1 | Selected Tetracyclic Tetrahydrofuran Derivatives Containing a Cyclic Amine Side Chain | FERNANDEZ-GADEA FRANCISCO JAVIER | 2008-09-04 | — | — | US | disclosed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20070191469-A1 | Novel tetracyclic tetrahydrofuran derivatives | JANSSEN-CILAG S.A. (ES) | 2007-08-16 | — | — | US | disclosed |
| US-20070191469-A1 | Novel tetracyclic tetrahydrofuran derivatives | JANSSEN-CILAG S.A. (ES) | 2007-08-16 | — | — | US | disclosed |
| US-7253180-B2 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| CN-1136191-C | Carboxy substituted carboxamide derivatives as tachykinin receptor antagonists | ������ҩ������˾ | 2004-01-28 | — | — | CN | disclosed |
| CN-1301253-A | Carboxy substituted carboxamide derivatives as tachykinin receptor antagonists | AVENTIS PHARMACEUTICAL INC (US) | 2001-06-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | MUS81, CDKL4, INTS6 | CYP1A2 330/4885TDP1 537/4885HTR1A 930/4885 |
| US-20070191469-A1 | Novel tetracyclic tetrahydrofuran derivatives | HTR2C, HTR2A, HTR1A | CYP1A2 118/4885TDP1 2025/4885HTR1A 3/4885 |
| US-20080214572-A1 | Selected Tetracyclic Tetrahydrofuran Derivatives Containing a Cyclic Amine Side Chain | HTR2C, HTR2A, HTR5A | CYP1A2 364/4885TDP1 2822/4885HTR1A 6/4885 |
| US-20210316006-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | BCR, MCL1, CD79B | CYP1A2 1243/4885TDP1 2182/4885HTR1A 982/4885 |
| US-20230382913-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | CYP1A2 494/4885TDP1 3839/4885HTR1A 2683/4885 |
| US-20230302142-A1 | Cytotoxic Agents | ANXA11, ANXA5, HAX1 | CYP1A2 3344/4885TDP1 823/4885HTR1A 1026/4885 |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | CYP1A2 635/4885TDP1 1870/4885HTR1A 2213/4885 |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | CYP1A2 4742/4885TDP1 2141/4885HTR1A 4388/4885 |
| US-20210380605-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | PRLHR, GLRA1, CXCR1 | CYP1A2 1902/4885TDP1 1310/4885HTR1A 457/4885 |
| US-20100009954-A1 | BETA-LACTAMASE INHIBITORY COMPOUNDS | MGAM, GUSB, LCT | CYP1A2 878/4885TDP1 2446/4885HTR1A 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.